Brian Lian, Viking Therapeutics CEO
November 5, 2024 06:30 AM EST
R&D
Manufacturing

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Kyle LaHucik

Senior Reporter

SAN AN­TO­NIO — Promis­ing da­ta don’t al­ways equal a stock pop.

Viking Ther­a­peu­tics pre­sent­ed what an­a­lysts thought were com­pelling da­ta on an oral …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times